Article Per Year (5 Year)
p-Index From 2019 - 2024
0.817
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran Brawijaya Majalah Kesehatan FKUB CRJIM (Clinical and Research Journal in Internal Medicine) Jurnal Penyakit Dalam Indonesia
Hermanto, Djoko Heri
Unknown Affiliation
Education Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health Other

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search

 1 
Peningkatan NT-proBNP dan cTn-I Serum Pasien Limfoma Non-Hodgkin's yang Menerima Kemoterapi Berbasis Doxorubicin Putra, Aditya Chandra; Hermanto, Djoko Heri; -, Wursito -
Jurnal Kedokteran Brawijaya Vol 29, No. 2 (2016)
Publisher : Fakultas Kedokteran Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jkb.2016.029.02.8

Abstract

Penelitian ini bertujuan menilai perubahan kadar cTn-I dan NT-proBNP serum pasien Limfoma Non-Hodgkin's (LNH) yang dikemoterapi berbasis doxorubicin (DOX). Penelitian menggunakan desain prospective cohort observational dengan kriteria inklusi yaitu pasien LNH usia 16 s/d 65 tahun, ECOG scale ≤2, serum kreatinin ≤1,5mg/dl, dan fungsi liver normal. Kriteria eksklusi antara lain memiliki PJK, penyakit katup jantung dengan gangguan hemodinamik, ekokardiografi prekemoterapi LVEF <50%, sedang atau riwayat iradiasi di dinding thorax. Sampel darah diambil sebelum dan 24 jam setelah kemoterapi. Dari 34 pasien yang diteliti, lansia 20 pasien, dewasa 13 pasien dan 1 pasien remaja. Sebanyak 33 pasien dengan skor ECOG 1. Kadar cTn-I 23 pasien meningkat 24 jam pascakemoterapi ke-1 dan berbeda bermakna jika dibandingkan kadar cTn-I prekemoterapi (p<0,001). Kadar NT-proBNP 11 pasien meningkat 24 jam pascakemoterapi ke-1 dan 22 pasien meningkat 24 jam pascakemoterapi ke-2. Kadar NT-proBNP pascakemoterapi ke-1 berbeda bermakna jika dibandingkan prekemoterapi (p<0,001). Kadar NT-proBNP pascakemoterapi ke-2 berbeda bermakna jika dibandingkan prekemoterapi (p<0,001). Kadar NT-proBNP dosis DOX 100mg/m2 LPT berbeda bermakna jika dibandingkan dosis 50mg/m2 LPT (p=0,001). Uji regresi logistik menunjukkan usia tua berhubungan dengan risiko peningkatan NT-proBNP (RR=6,271 (CI:1,295, 30,382), p=0,023). Kesimpulannya, terdapat peningkatan kadar cTn-I dan NT-proBNP pada pasien LNH setelah kemoterapi berbasis DOX. Kata Kunci: Doxorubicin, cTn-I, Limfoma Non-Hodgkin's, NT-proBNP
Pseudotumor Hemofilia, Suatu Komplikasi Hemofilia yang Jarang nurshanty, ade; hermanto, djoko heri
Jurnal Kedokteran Brawijaya Vol 29, No. 2 (2016)
Publisher : Fakultas Kedokteran Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jkb.2016.029.02.13

Abstract

Pseudotumor adalah kista berisi darah pada jaringan lunak atau tulang. Satu sampai dua persen hemofilia berat menyebabkan pseudotumor, yang bisa berasal dari jaringan lunak atau pada subperiosteal atau area intraosseus. Pseudotumor jarang terjadi namun merupakan komplikasi hemofilia yang berbahaya. Kami laporkan kasus pseudotumor hemofilia pada seorang laki-laki 27 tahun dengan keluhan bengkak pada paha kanan yang muncul tiba-tiba, merata dari pangkal paha sampai lutut. Keluhan hilang timbul, bergantian pada kaki kanan kiri sejak 2002. Riwayat perdarahan yang sulit berhenti 15 tahun sebelumnya. Pemeriksaan MRI (magnetic resonansi imaging) menunjukkan massa intra muskular regio femur dekstra 1/3 proksimal hingga 1/3 tengah dan massa intra muskular regio femur sinistra 1/3 proksimal melibatkan kompartemen anterior dan bone marrow replacement. Didapatkan Hemofilia A sedang dengan APTT memanjang (faktor VIII 7%) pada pemeriksaan darah. Pasien membaik dengan terapi konservatif, yaitu pemberian faktor VIII. Kata Kunci: Hemofilia A, pseudotumor hemofilia
The Effect of Vitamin E on Oral Mucositis Induced by Chemotherapy in Non-Hodgkin Lymphoma Patients Receiving Chemotherapy Hermanto, Djoko Heri; Habsari, Indri; Machsoos, Budi Darmawan
Clinical and Research Journal in Internal Medicine Vol 1, No 2 (2020): New: The Second Issue is Coming!
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2020.001.02.5

Abstract

Chemotherapy-induced mucositis is a side effect of chemotherapy that often occurs in patients with solid tumors and lymphoma. Oral mucositis can affect nutritional status and the risk of infection, both local and systemic. Antioxidant Vitamin E is beneficial for the prevention and therapy of both oral and gastrointestinal mucositis. Aim: To determine the effect of vitamin E therapy on the incidence of oral mucositis in non-Hodgkin lymphoma (NHL) patients receiving chemotherapy. Methods: This is a single-blind experimental study in 62 NHL patients undergoing chemotherapy who meet the inclusion criteria. Patients who met the inclusion criteria were randomly divided into 2 groups, namely 31 patients (treatment group) received vitamin E 400 mg / IU per day for 7 days and 31 patients in the placebo group. The incidence and grade of oral mucositis were observed on day 7. Statistical analysis used Chi-Square and Mann Whitney test according to the data type. Results: a total of 67% NHL patients were male, most of whom were over 46 years of age and as many as 50% of patients used chemotherapy regimens RCHOP and CHOP. There was an incidence of oral mucositis in 35% in the placebo group and 12.9% in the treated group (p = 0.038). In the placebo group, there were 4.8% of patients with grade 2 and 3 oral mucositis, which was not found in the therapy group. Conclusion:  treatment with vitamin E in NHL patients undergoing chemotherapy can prevent chemotherapy-induced oral mucositis and prevent its severity.
EFEK SAMPING KEMOTERAPI BERBASIS KARBOPLATIN TERHADAP FUNGSI GINJAL PADA PASIEN KANKER GINEKOLOGI Hermanto, Djoko Heri; Mayangsari, Elly; Fadriyana, Aulia Putri
Majalah Kesehatan FKUB Vol 8, No 3 (2021): Majalah Kesehatan
Publisher : Faculty of Medicine Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.majalahkesehatan.2021.008.03.3

Abstract

Karboplatin merupakan regimen platinum terapi lini pertama pada pengobatan kanker ginekologi. Karboplatin analog dengan cisplatin, tetapi lebih stabil dan memiliki lebih sedikit efek samping. Namun, pemberian karboplatin dalam jangka panjang dapat meningkatkan akumulasinya pada tubuh sehingga meningkatkan efek samping, salah satunya pada ginjal. Tujuan penelitian ini untuk mengetahui efek samping kemoterapi berbasis karboplatin terhadap fungsi ginjal pada pasien kanker ginekologi di RSUD Dr. Saiful Anwar Malang, dengan parameter penurunan laju filtrasi glomerulus (LFG) dan peningkatan kadar blood urea nitrogen (BUN). Desain penelitian adalah analitik observasional cross-sectional dengan mengumpulkan data rekam medis dari pasien kanker ginekologi. Jumlah subjek diperoleh 45 pasien yang memenuhi kriteria inklusi dan eksklusi. Karakteristik subjek penelitian menunjukkan bahwa sebagian besar pasien dalam rentang usia 40-49 dan 50-59 tahun masing-masing sebanyak 15 pasien (33,33%). Berdasarkan hasil uji t berpasangan diketahui bahwa tidak ada penurunan yang signifikan pada LFG pre dan post kemoterapi (p = 0,254) sedangkan berdasarkan hasil uji Wilcoxon didapatkan tidak ada peningkatan yang signifikan pada kadar BUN pre dan post kemoterapi (p = 0,498). Dari hasil penelitian, dapat disimpulkan bahwa tidak terdapat penurunan laju filtrasi glomerulus (LFG) dan peningkatan kadar BUN pada pasien kanker ginekologi yang mendapat kemoterapi berbasis karboplatin sebanyak 6 siklus di RSUD Dr. Saiful Anwar Malang. 
Clinical Response of Convalescent Plasma Therapy in COVID-19 Patients in Dr. Saiful Anwar General Hospital Burhan, Niniek Budiarti; Brahmantyo, Herwindo Pudjo; Hermanto, Djoko Heri; Arsana, Putu Moda
Jurnal Kedokteran Brawijaya Vol 31, No 4 (2021)
Publisher : Fakultas Kedokteran Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jkb.2021.031.04.5

Abstract

The use of convalescent plasma has been beneficial for more than a century to treat various infections.  The lack of effective treatment currently available for COVID-19 has reemerged the use of convalescent plasma as a potential therapeutic option. This is an observational descriptive study in 13 COVID-19 patient who got convalescent Plasma. Consist of 11 (84%) male patient, 2 (16%) female patient. Divided into two groups based on severity, and outcome. 38% patient included in severe disesase and 62% patient in critically Ill condition. 30% patient who got convalescent plasma deceased, and 70% had a resolve condition.
Comparison of Socal Score and Hasford Score Against the Response of Imatinib Mesylate Therapy in Patients with Chronic Granulocytic Leukemia in dr. Saiful Anwar Hospital Malang Somarnam, Somarnam; Machsoos, Budi Darmawan; Hermanto, Djoko Heri
Jurnal Penyakit Dalam Indonesia Vol. 6, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. The Socal and Hasford scores developed before the era of tirosine kinase inhibitor (TKI) therapy to provide predictions and prognosis for the results of therapy for chronic myeloid leukemia patients (CML). Until now the superiority of Socal and Hasford scores is still debated in predicting the results of therapy in the era of TKI. Imatinib mesylat is a first line TKI in the treatment of CML. This study aims to determine the superior predictive score in predicting hematological and molecular response of patients treated with imatinib mesylate. Methods. A survey study was conducted with data taken retrospectively from medical records. Subjects were chronic phase LGK patients who had at least been given imatinib mesylate therapy for 12 months. Calculation of Socal and Hasford scores was carried out based on patient data when first receiving Imatinib. To see the difference in distribution between the two scores, a marginal homogeneity statistic was used. To see the process of changing the response of patients treated with Imatinib, a suitability test using chi-square and Fischer was conducted with a significant p value, p 0,05. Conclusion. There was no significant difference between Hasford and Socal scores in predicting hematological responses and molecular responses of chronic CML patients. Socal scores and Hasford scores can be used to predict hematological and molecular responses in chronic CML patients treated with imatinib mesylate.
Co-Authors -, Wursito - Arsana, Putu Moda Brahmantyo, Herwindo Pudjo Fadriyana, Aulia Putri Habsari, Indri Machsoos, Budi Darmawan Mayangsari, Elly Niniek Budiarti B Nurshanty, Ade Putra, Aditya Chandra Somarnam, Somarnam